Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 670-677

  Craparo, Emanuela Fabiola ^a   Bondì, Maria Luisa ^b   Pitarresi, Giovanna ^a   Cavallaro, Gennara ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

Author keywords

Alzheimer's disease; Movement disorders Parkinson's disease; Multiple sclerosis; Neuropsychopharmacology

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; ARGINYLGLYCYLASPARTIC ACID; CLOZAPINE; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; FERULIC ACID; FLUOROURACIL; GLYCOPROTEIN P INHIBITOR; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LIPID; LIPOSOME; LOPERAMIDE; MACROGOL; MONOCLONAL ANTIBODY; MRZ 2 576; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; NITRENDIPINE; POLOXAMER; POLYMER; POLYSORBATE 80; PREDNISOLONE; QUININE; RILUZOLE; THIAMINE; TRANSFERRIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; COLLOID; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; DRUG TRANSPORT; ENDOCYTOSIS; HUMAN; MICELLE; NONHUMAN; PARTICLE SIZE; PARTICULATE MATTER; PHOSPHOLIPID BILAYER; REVIEW; RNA INTERFERENCE;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICELLES; NANOPARTICLES; PARTICLE SIZE; POLYMERS; SURFACE PROPERTIES;

EID: 82355175419     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00199.x     Document Type: Review

References (64)

1. Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. J Pharm Sci 2008;97:3518-3590.
2. Moses MA, Brem H, Langer R. Advancing the field of drug delivery: Taking aim at cancer. Cancer Cell 2003;4:337-341.
3. Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Current Pharm Design 2004;10:1355-1363.
4. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: Chemical modifications of drugs or drug-nanoparticles Drug Discov Today 2008;13:1099-1106.
5. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127:97-109.
6. Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G. Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain. Curr Topics Med Chem 2009;9:182-196.
7. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010;37:48-57
8. Li S-D, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496-504.
9. Torchilin VP. Multifunctional nanocarriers. Adv Drug Del Rev 2006;58:1532-1555.
10. Van Butsele K, Jerome R, Jerome C. Functional amphiphilic and biodegradable copolymers for intravenous vectorisation. Polymer 2007;48:7431-7443.
11. Park JH, Lee S, Kim JH, Park K, Kim K, Kwon IC. Polymeric nanomedicine for cancer therapy. Prog Polymer Sci 2008;33:113-137.
12. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307:93-102.
13. Ben-Shabat S, Kumar N, Domb AJ. PEG-PLA block copolymer as potential drug carrier: Preparation and characterization. Macromol Biosci 2006;6:1019-1025.
14. Hu Y, Xie J, Wah Tong Y, Wang C-H. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Contl Release 2007;118:7-17.
15. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Del Rev 2008;60:1615-1626.
16. Ricci M, Blasi P, Giovagnoli S, Rossi C. Delivering drugs to the central nervous system: A medicinal chemistry or a pharmaceutical technology issue Curr Med Chem 2006;13:1707-1725.
17. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 2008;4:273-282.
18. Shapira I, Budman DR, Bradley T, Gralla R. Evolving lipid-based delivery systems in the management of neoplastic disease. Oncol Rev 2009;3:113-124.
19. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003;126:1895-1904.
20. Zhang Y, Zhang Y-F, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004;10:3667-3677.
21. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. J NeuroRx 2005;2:99-107.
22. Zhu C, Zhang Y, Zhang YF, Yi Li J, Boado RJ, Pardridge WM. Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J Gene Med 2004;6:906-912.
23. Schlachetzki F, Zhang YF, Boado RJ, Pardridge WM. Gene therapy of the brain. Neurology 2004;62:1275-1281.
24. Pardridge WM. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev 2007;59:141-152.
25. Soni V, Kohli DV, Jain SK. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target 2008;16:73-78.
26. Qin J, Chen D, Hu H, Cui Q, Qiao M, Chen B. Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain. Chem Pharm Bull 2007;55:1192-1197.
27. Bunjes H, Siekmann B. Manufacture, characterization and application of solid lipid nanoparticles as drug delivery system. In: Deleers M, Pathak Y, Thassu YD, editors. Nanoparticulate drug delivery systems. New York: Informa Healthcare, 2007;213-268.
28. Ishida T, Harada M, Wang X-Y, Ichihara M, Irimura K, Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Contl Release 2005;105:305-317.
29. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-1272.
30. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009;71:161-172.
31. Reddy JS, Venkateswarlu V. Novel delivery systems for drug targeting to the brain. Drugs Future 2004;29:63-83.
32. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999;16:751-757.
33. Bondì ML, Craparo EF. Solid lipid nanoparticles for applications in gene therapy: A review of the state of the art. Expert Opin Drug Del 2010;7:7-18.
34. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81.
35. Bondì ML, Craparo EF, Giammona G, Drago F. Brain-targeted solid lipid nanoparticles (SLNs) containing riluzole: Preparation, characterisation and biodistribution. Nanomedicine 2010;5:25-32.
36. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Del Rev 2007;59:454-477.
37. Panyam J, Chavanpatil M. Lipid-derived nanoparticles for brain-targeted drug delivery, PCT WO2008024753, 2008.
38. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Contl Release 2005;107:215-228.
39. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target 2006;14:632-645.
40. Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. Brain uptake of thiamine-coated nanoparticles. J Contl Release 2003;93:271-282.
41. Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007;59:935-940.
42. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloid Surf B 2010;75:1-18.
43. Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 2008;1200:159-168.
44. Mohamed F, Van Der Walle CF. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 2008;97:71-87.
45. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, Jiang X. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. J Contr Release 2009;134:55-61.
46. Silva GA. Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier. Surg Neurol 2007;67:113-116.
47. Das D, Lin S. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J Pharm Sci 2005;94:1343-1353.
48. Smith MW, Gumbleton M. Endocytosis at the blood-brain barrier: From basic understanding to drug delivery strategies. J Drug Targ 2006;14:191-214.
49. Gulyaev AE, Gelperina SE, Skida AS, Antropov GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999;16:1564-1569.
50. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 2000;49:103-109.
51. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002;10:317-325.
52. Lu W, Tan Y-Z, Hu K-L, Jiang X-G. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int J Pharm 2005;295:247-260.
53. Tosi G, Costantino L, Rivasi F, et al. Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 2007;122:1-9.
54. Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L. Nanoparticles as drug delivery agents specific for CNS: In vivo biodistribution. Nanomed: Nanotechnol, Biol Med 2009;5:369-377.
55. Aktas Y, Yemisci M, Andrieux K, et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 2005;16:1503-1511.
56. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor monoclonal antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009;71:251-256.
57. Gosk S, Vermehren C, Storm G, Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab 2004;24:1193-1204.
58. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream Science 2004;303:1818-1822.
59. Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug Deliv 2006;3:139-162.
60. Torchilin VP. Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res 2007;24:1-16.
61. Craparo EF, Ognibene MC, Casaletto MP, Pitarresi G, Teresi G, Giammona G. Biocompatible polymeric micelles with polysorbate 80 for brain targeting. Nanotechnology 2008;19:485603 (12pp).
62. Batrakova EV, Kabanov AV. Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Contl Release 2008;130:98-106.
63. Liu L, Guo K, Lu J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 2008;29:1509-1517.
64. Liu L, Venkatraman SS, Yang YY, et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolym - Peptide Sci Sect 2008;90:617-623.